GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » EV-to-EBITDA

Clover Biopharmaceuticals (HKSE:02197) EV-to-EBITDA : -0.90 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Clover Biopharmaceuticals's enterprise value is HK$44.18 Mil. Clover Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-49.30 Mil. Therefore, Clover Biopharmaceuticals's EV-to-EBITDA for today is -0.90.

The historical rank and industry rank for Clover Biopharmaceuticals's EV-to-EBITDA or its related term are showing as below:

HKSE:02197' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.05   Med: -1.39   Max: 1.38
Current: -0.9

During the past 5 years, the highest EV-to-EBITDA of Clover Biopharmaceuticals was 1.38. The lowest was -5.05. And the median was -1.39.

HKSE:02197's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.54 vs HKSE:02197: -0.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Clover Biopharmaceuticals's stock price is HK$0.405. Clover Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.120. Therefore, Clover Biopharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Clover Biopharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Clover Biopharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals EV-to-EBITDA Chart

Clover Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- - -1.66 -0.72 -6.72

Clover Biopharmaceuticals Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial -1.66 - -0.72 - -6.72

Competitive Comparison of Clover Biopharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Clover Biopharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clover Biopharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's EV-to-EBITDA falls into.



Clover Biopharmaceuticals EV-to-EBITDA Calculation

Clover Biopharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=44.180/-49.3
=-0.90

Clover Biopharmaceuticals's current Enterprise Value is HK$44.18 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clover Biopharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-49.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clover Biopharmaceuticals  (HKSE:02197) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Clover Biopharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.405/-0.120
=At Loss

Clover Biopharmaceuticals's share price for today is HK$0.405.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clover Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.120.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Clover Biopharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Clover Biopharmaceuticals (HKSE:02197) Business Description

Traded in Other Exchanges
N/A
Address
1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN
Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.
Executives
Liang Peng 2101 Beneficial owner
Liang Joshua G 2501 Other
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd. 2102 Investment manager
Aut-xxi Investment Holdings Limited 2201 Interest of corporation controlled by you
Jnry V Holdings Limited 2101 Beneficial owner
Aut-xxi Hk Holdings Limited 2101 Beneficial owner
Aut-xxi Holdings Limited 2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p. 2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Super Novel International Limited 2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines